Abbott Laboratories (ABT) Revenue — Quarter Ended Sep 30, 2024
Revenue for the quarter increased compared to the prior quarter and also rose relative to the same quarter last year. The sequential and year-over-year gains reflect continued growth in the reported period.
Key takeaway
Quarter ended Sep 30, 2024 · FY2024 Q3
Revenue for the quarter increased compared to the prior quarter and also rose relative to the same quarter last year. The sequential and year-over-year gains reflect continued growth in the reported period.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$10.6B
Revenue reported for this quarter.
Quarter-over-quarter
+2.5%
Change from the immediately preceding quarter.
Year-over-year
+4.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$41.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2023 | $10.2B | +1.5% |
| Mar 31, 2024 | $10B | +2.2% |
| Jun 30, 2024 | $10.4B | +4.0% |
| Sep 30, 2024 | $10.6B | +4.9% |
Revenue performance
The reported revenue direction was positive, with a higher total than in the immediately preceding quarter. The increase from the same quarter one year earlier was also positive.
Quarterly comparison
Compared to the prior quarter, revenue improved, and the year-over-year comparison also showed an increase. The trailing twelve-month revenue was higher than the current quarter's annualized run rate.
What to watch
The filing context discusses long-term investments and liquidity, but no direct causal link to revenue is provided.